The first wave of PARP inhibitors has improved outcomes ... In doing so, IDX-1197 triggers a phenomenon known as synthetic lethality, which is defined by cell death resulting from the simultaneous ...

The sensitizing effect of CDK5 suppression is not limited to PARP inhibition but is also associated ... genomics & identification of synthetic lethal interactions RNAi is the mechanism whereby ...

One important problem that may arise during PARP inhibitor treatment is the development of resistance. Even BRCA-deficient mouse tumors were reported to acquire resistance to PARP inhibitors.

Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) are promising cancer treatments because they block ... they efficiently targeted HR-deficient cancer cells for apoptosis through a process called ...

These cancer cells have switched to this backup system to repair DNA damage and by turning it off, PARP inhibitors cause them to die from a process known as “synthetic lethality” as mutations ...

PARP & DDR therapeutics are exploding thanks to numerous novel next generation synthetic lethal targets reaching an inflection point. The PARP & DDR Inhibitors Summit is your only industry focused ...

China NMPA grants marketing authorization to IMPACT Therapeutics’ Senaparib for 1L maintenance therapy in ovarian cancer: Shanghai Saturday, January 18, 2025, 15:30 Hrs [IST] IM ...

While all poly ADP-ribose polymerase (PARP) inhibitors improved progression-free survival, olaparib significantly extended overall survival (OS), making it a preferred option.

16, 2025 /PRNewswire/ -- IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality ...

IMPACT Therapeutics has assembled one of the most comprehensive DNA damage responses (DDR) global pipeline of novel drug candidates generated by in-house discovery efforts and is expanding to other ...

TNG348 is a novel, selective inhibitor of USP1 (ubiquitin-specific ... believe we can make for patients by advancing multiple synthetic lethality programs across our clinical-stage pipeline.” ...